Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Letrozole Indication as First-Line Therapy Recommended

January 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 1
Volume 10
Issue 1

BETHESDA, Md-Seconding the advice of a Food and Drug Administration review team, the Oncologic Drugs Advisory Committee (ODAC) has recommended that the FDA approve Femara tablets (letrozole, Novartis) as first-line therapy in postmenopausal women with advanced breast cancer.

BETHESDA, Md—Seconding the advice of a Food and Drug Administration review team, the Oncologic Drugs Advisory Committee (ODAC) has recommended that the FDA approve Femara tablets (letrozole, Novartis) as first-line therapy in postmenopausal women with advanced breast cancer.

The unanimous vote followed the company’s presentation of a study that found letrozole significantly more effective than tamoxifen (Nolvadex) in this setting and a highly favorable review of the drug by the FDA’s panel of experts. "The FDA analysis did not differ significantly from the sponsor’s," said FDA reviewer Martin Cohen, MD.

Letrozole is a nonsteroidal aromatase inhibitor that is given at 2.5 mg daily to block estrogen synthesis. The FDA approved the drug for second-line breast cancer therapy in 1997.

Novartis presented data from two prospective, double-blind, multicenter, randomized phase III trials. Its pivotal study, designated 025, compared letrozole 2.5 mg with tamoxifen 20 mg in 916 women—equally divided between the two drugs—treated at 201 centers in 29 countries worldwide.

The company’s supportive study involved 324 women (154 on letrozole and 170 on tamoxifen) treated at 55 centers in 16 countries with the same dosages.

The pivotal study’s primary endpoint was time to progression, which proved to be 9.4 months for letrozole and 6.0 months for tamoxifen.

"The median time to progression was prolonged with use of Femara by 56%," said Margaret Dugan, MD, group leader for oncology clinical development and research at Novartis. "Femara was statistically significantly superior to tamoxifen in time to progression, reducing the risk of progression by 30%. These treatment differences favoring Femara are clinically important to patients."

Letrozole had a time to treatment failure of 9.1 months vs 5.7 months for tam-oxifen, and a significantly higher overall rate of confirmed objective tumor response. The letrozole response rate was 30% (34 complete responders, 103 partial), compared with 20% (13 complete, 79 partial) for tamoxifen.

The finding represents "a 71% higher odds of responding to Femara than tamoxifen," Dr. Dugan said. Dr. Cohen called the difference in the two response rates "highly significant."

The FDA analysis of response was even more positive than that of the company; the agency reported a response rate of 32% for letrozole and 21% for tamoxifen. However, the FDA’s analysis of the response duration was different from the company’s findings. Novartis reported 17 months for letrozole and 16.5 months for tamoxifen; the FDA put the response duration at 11.5 months for letrozole and 10.3 months for tamoxifen.

Adverse events were similar in the two groups, according to the FDA. They included peripheral thromboembolic events (2% in each group); cardiovascular events (2% for letrozole and 1% for tamoxifen); cerebrovascular events (1% for letrozole vs 2% for tamoxifen); fractures (5% vs 4%); and ocular toxicity (2% vs 1%). Hot flashes occurred in 18% of the letrozole patients and in 16% of those taking tamoxifen. One case of endometrial cancer occurred in the tamoxifen group.

Although study 025 has not progressed yet to the point of yielding valid survival data, the FDA agreed that this information was not needed, in light of the clinical and safety data from the trial.

Articles in this issue

ODAC Recommends Campath for FDA Approval for Refractory CLL
‘IrinoGem’ Active and Well Tolerated in Pancreatic Cancer
STI571 Studies Help Validate Molecular Targeting in CML
Outpatient Mylotarg Therapy Cuts Costs in Relapsed AML
STI571 Proves Effective in Patients With Interferon-Failure CML
Prostate Cancer Patients Tolerate Higher 3D Conformal RT Doses

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 6th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 6th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 6th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
September 6th 2025
Podcast

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
September 6th 2025
Article

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
September 6th 2025
Article
Related Content

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
September 6th 2025
Article

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
September 6th 2025
Podcast

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
September 6th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
September 6th 2025
Podcast

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
September 6th 2025
Article

Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis.

GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer

Sherry Shen, MD;Bethina Liu, MD;Chad Fanti, MD;Maria Bromberg, MPH;Yuan Chen, PhD;Cassandra Chang;Neil M. Iyengar, MD
September 6th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.